Forian Inc
NASDAQ:FORA
Forian Inc
Research & Development
Forian Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Forian Inc
NASDAQ:FORA
|
Research & Development
-$2.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Research & Development
-$750.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-29%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Research & Development
-$108.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Research & Development
-$93m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Research & Development
-$88.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Research & Development
-$48.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Forian Inc
Glance View
Forian, Inc. engages in the provision of healthcare information, analytics and technology services. The company is headquartered in Newtown, Pennsylvania and currently employs 138 full-time employees. The company went IPO on 2021-03-03. The firm provides software solutions, data and predictive analytics to optimize the operational, clinical and financial performance of its healthcare, cannabis, and government customers. Its BioTrack vertically integrated point-of-sale, manufacturing, delivery and cultivator software solution is a commercial platform in the cannabis industry, serving dispensaries, cultivators, manufacturers and distributors within 38 states and Puerto Rico. Its Cannalytics software as a service (SaaS)-based analytics solution is a platform that provides clients with a configurable and flexible presentation of business performance. Its real world experience (RWE) solutions are designed to enable the integration otherwise unconnected and disparate data to enable near real-time surveillance of adverse events and to study the clinical economic and social impacts of various therapeutic alternatives, including those derived from cannabinoids and psychedelics.
See Also
What is Forian Inc's Research & Development?
Research & Development
-2.4m
USD
Based on the financial report for Sep 30, 2025, Forian Inc's Research & Development amounts to -2.4m USD.
What is Forian Inc's Research & Development growth rate?
Research & Development CAGR 3Y
38%
Over the last year, the Research & Development growth was -86%. The average annual Research & Development growth rates for Forian Inc have been 38% over the past three years .